FDA authorizes Watmind USA’s OTC COVID and flu test

Watmind USA announced that the FDA granted it emergency use authorization (EUA) for its SpeedySwab […]

Watmind USA announced that the FDA granted it emergency use authorization (EUA) for its SpeedySwab COVID + flu A&B self test.

EUA covers over-the-counter (OTC) and point-of-care (POC) use. The Jackson, Mississippi-based company developed the test in partnership with the NIH’s Rapid Acceleration of Diagnostics (RADx) Independent Test Assessment Program (ITAP).

Watmind USA aims to revolutionize home diagnostics. The company says it designed SpeedySwab to help symptomatic individuals aged two and older quickly identify if their symptoms occur due to COVID-19, Influenza A or Influenza B. With a user-friendly, step-by-step process, the test utilizes lateral flow assay (LFA) technology.

According to a news release, the test offers a cost-effective option that distinguishes between the symptoms of the similar viruses.

“Receiving the EUA for our SpeedySwab test marks a significant milestone in our commitment to advancing public health,” said Dan Davis, CEO of Watmind USA. “As we navigate the ongoing challenges of COVID-19 and influenza A&B strains, our goal is to provide accessible and rapid at-home testing solutions that empower individuals to proactively manage their health from the comfort of their homes, while minimizing the spread of such diseases. Watmind USA is proud to support critical public health initiatives.”

Original Article (https://www.massdevice.com/fda-authorizes-watmind-covid-flu-test/)